The recognition that elevated FGF23 and decreased Klotho are the first two biochemical alterations observed in the earliest stages of CKD (stages 1 and 2) has led us to the need to implement strategies to control these molecules in order to minimize their deleterious effects [55]. The gene discussed is FGF23; the disease is chronic kidney disease.